Committed to innovation and striving for long-term progress: interpretation of research and innovation chapter in the Global Tuberculosis Report 2024

doi:10.19982/j.issn.1000-6621.20240559

Abstract

Abstract:

Accelerating innovative research and development in the field of tuberculosis (TB) is one of the crucial domains to end the disease. On October 29, 2024, the World Health Organization (WHO) released the Global Tuberculosis Report 2024. The author summarizes the research and innovation highlights of new diagnostic technologies, new drugs and regimens, and new vaccines as outlined in the report, and analyzes them in conjunction with research progress in related fields in China. The aim is to keep China’s TB professionals better informed about the latest global research development in TB prevention and control, and to serve as a reference for further conducting original research and technology development.

Key words: Tuberculosis, Research, Consensus development conference

CLC Number:

Shu Wei, Liu Yuhong. Committed to innovation and striving for long-term progress: interpretation of research and innovation chapter in the Global Tuberculosis Report 2024[J]. Chinese Journal of Antituberculosis, 2025, 47(2): 137-141. doi: 10.19982/j.issn.1000-6621.20240559

References 16

[1]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[2]	Resolution 78/5: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. New York: United Nations, 2023.
[3]	World Health Organization. WHO launches the TB research tracker, an online platform to track progress in TB research. Geneva: World Health Organization, 2023.
[4]	World Health Organization. Geospatial overview of phenotypic and sequencing information[DB/OL].[2024-12-11]. https://hq_globaltuberculosisprogramme.createsend1.com/t/d-l-eviig-ihkktihjjl-t/.
[5]	World Health Organization. Funding a tuberculosis-free future: an investment case for screening and preventive treatment. Geneva: World Health Organization, 2024.
[6]	World Health Organization. Fourth WHO consultation on the translation of tuberculosis research into global policy guidelines. Geneva: World Health Organization, 2024.
[7]	BRICS TB Research Network[DB/OL].[2024-12-11]. http://bricstb.samrc.ac.za.
[8]	Treatment Action Group. Tuberculosis research funding trends 2005—2022[EB/OL]. [2024-12-11]. https://www.treatmentactiongroup.org/resources/tbrd-report/tbrd-report-2023/.
[9]	Nyang’wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med, 2024, 12(2): 117-128. doi:10.1016/S2213-2600(23)00389-2.
[10]	World Health Organization. WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2022.
[11]	World Health Organization. Key updates to the treatment of drug-resistant tuberculosis Rapid communication. Geneva: World Health Organization, 2024.
[12]	Cevik M, Thompson LC, Upton C, et al. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis, 2024, 24(9): 1003-1014. doi:10.1016/S1473-3099(24)00223-8. pmid: 38768617
[13]	Project to Accelerate New Treatment for Tuberculosis.,Aug. 9, 2023 PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens[EB/OL].(2023-08-09)[2024-12-11]. https://www.pan-tb.org/newsroom/.
[14]	Gao J, Gao M, Du J, et al. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT. Trials, 2024, 25(1): 227. doi:10.1186/s13063-024-07946-9.
[15]	Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2019, 381(25): 2429-2439. doi:10.1056/NEJMoa1909953.
[16]	李军丽, 郭晓楠, 梁艳, 等. 结核病疫苗研究进展与突破. 中国防痨杂志, 2024, 46(10): 1171-1184. doi:10.19982/j.issn.1000-6621.20240296.